Larimar Therapeutics, Inc.(LRMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LRMR Larimar Therapeutics, Inc.

Trading 08-05 13:45:40 EDT

4.17

+0.06

+1.34%

High4.29	Low4.11	Vol774.57K
Open4.11	D1 Closing4.11	Amplitude4.26%
Mkt Cap433.16M	Tradable Cap247.78M	Total Shares104.00M
T/O3.24M	T/O Rate1.30%	Tradable Shares59.49M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LRMR","market":"US","secType":"STK","nameCN":"Larimar Therapeutics, Inc.","latestPrice":4.165,"timestamp":1785951940160,"preClose":4.11,"halted":0,"volume":774569,"delay":0,"changeRate":0.013381995133819881,"floatShares":59489900,"shares":104000000,"eps":-2.08756,"marketStatus":"Trading","change":0.055,"latestTime":"08-05 13:45:40 EDT","open":4.11,"high":4.285,"low":4.11,"amount":3241590.6292250003,"amplitude":0.042579,"askPrice":4.17,"askSize":601,"bidPrice":4.16,"bidSize":1571,"shortable":3,"etf":0,"ttmEps":-2.08756,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1785960000000},"marketStatusCode":2,"adr":0,"listingDate":1403150400000,"exchange":"NASDAQ","adjPreClose":4.11,"preHourTrading":{"tag":"盘前","latestPrice":4,"preClose":4.11,"latestTime":"08:46 EDT","volume":4213,"amount":16237.0359734,"timestamp":1785933988749,"change":-0.11,"changeRate":-0.026764,"amplitude":0.053479},"postHourTrading":{"tag":"盘后","latestPrice":4.04,"preClose":4.11,"latestTime":"19:41 EDT","volume":5886,"amount":24054.93,"timestamp":1785886864660,"change":-0.07,"changeRate":-0.017032,"amplitude":0.021898},"volumeRatio":0.927263,"impliedVol":1.9888,"impliedVolPercentile":0.502},"requestUrl":"/m/hq/s/LRMR","defaultTab":"news","newsList":[{"id":"2656530538","title":"Larimar Therapeutics Q2 EPS USD -0.3","url":"https://stock-news.laohu8.com/highlight/detail?id=2656530538","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656530538?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:00","pubTimestamp":1785841205,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nPLXRXRK87:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LRMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656530430","title":"Larimar Therapeutics - Projects Cash Runway into Q3 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2656530430","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656530430?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:00","pubTimestamp":1785841205,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nPLXRXRK87:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LRMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656308055","title":"Larimar Therapeutics Q2 Net Income USD -32.782 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2656308055","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656308055?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:00","pubTimestamp":1785841205,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nPLXRXRK87:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LRMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656530844","title":"Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2656530844","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656530844?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:00","pubTimestamp":1785841204,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nTUA92TBLY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LRMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651790170","title":"Exploring 3 High Growth Tech Stocks In The US Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2651790170","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651790170?lang=en_us&edition=fundamental","pubTime":"2026-07-14 19:08","pubTimestamp":1784027291,"startTime":"0","endTime":"0","summary":"In the last week, the United States market has stayed flat, yet it has risen 19% over the past year, with earnings expected to grow by 18% annually in the coming years. In such a dynamic environment, identifying high growth tech stocks can be key for investors seeking to capitalize on innovation and robust financial performance.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rzlt/rezolute/news/exploring-3-high-growth-tech-stocks-in-the-us-market-80","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rzlt/rezolute/news/exploring-3-high-growth-tech-stocks-in-the-us-market-80","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RZLT","LU2125154778.USD","LPTH","LU0128526141.USD","BK4161","BK4139","BK4157","LU2125154935.USD","HI","LU2360032135.SGD","LRMR","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650748915","title":"Larimar Therapeutics director buys $167K in common stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2650748915","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650748915?lang=en_us&edition=fundamental","pubTime":"2026-07-09 04:10","pubTimestamp":1783541411,"startTime":"0","endTime":"0","summary":"In a regulatory filing, Larimar Therapeutics (LRMR) disclosed that its director, Thomas Hamilton, bought 50,000 shares of common stock on July 6th ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/larimar-therapeutics-director-buys-167k-in-common-stock-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/larimar-therapeutics-director-buys-167k-in-common-stock-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","LRMR","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650903915","title":"Larimar Therapeutics Director Thomas Edward Hamilton Acquires USD 166,890 of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2650903915","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650903915?lang=en_us&edition=fundamental","pubTime":"2026-07-09 04:06","pubTimestamp":1783541177,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics director Thomas Edward Hamilton acquires USD 166,890 of common sharesLarimar Therapeutics director Thomas Edward Hamilton bought 50,000 common shares at a weighted-average price o","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nNDL16NRLc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Larimar Therapeutics Director Thomas Edward Hamilton Acquires USD 166,890 of Common Shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LRMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648696779","title":"Adobe, Larimar, Palantir, Chevron, eXp Trending With Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2648696779","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648696779?lang=en_us&edition=fundamental","pubTime":"2026-07-04 17:02","pubTimestamp":1783155759,"startTime":"0","endTime":"0","summary":"Analysts are intrested in these 5 stocks: ( ($ADBE) ), ( ($LRMR) ), ( ($PLTR) ), ( ($CVX) ) and ( ($AGNT) ). Here is a breakdown of their recent","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/weekend-updates/adobe-larimar-palantir-chevron-exp-trending-with-analysts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/weekend-updates/adobe-larimar-palantir-chevron-exp-trending-with-analysts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765646.SGD","LRMR","LU0300736492.USD","LU0472753341.HKD","LU0640476718.USD","IE00B2Q91V27.USD","LU2129689605.HKD","LU1267930730.SGD","LU0965509283.SGD","LU0889565833.HKD","BK4554","LU0109392836.USD","LU2089283258.USD","BK4585","BK4613","IE00B19Z9Z06.USD","IE00BFXG0V08.USD","LU2210150020.SGD","BK4543","LU0511384066.AUD","LU0612318385.USD","LU0057025933.USD","BK4201","LU2381873111.SGD","LU0345781412.USD","LU1861559042.SGD","PLTU","PLTZ","IE0002270589.USD","BK4566","LU0289739343.SGD","LU2317271919.USD","LU0348723411.USD","LU1235294995.USD","LU1691799644.USD","SGXZ51526630.SGD","FTXN","PLTD","LU0345770308.USD","LU0320765489.SGD","LU1803068979.SGD","SHLD","LU0320765059.SGD","PLYY","BK4527","IE00B19Z3B42.SGD","LU0345780950.USD","LU1261432733.SGD","BK4023","LU2360032135.SGD","BK4581","LU0265550946.USD","BK4528","BK4533","LU0314104364.USD","LU0289961442.SGD","LU0417517546.SGD","LU0456854461.SGD","LU1674673428.USD","PTIR","LU1280957306.USD","LU0612318971.USD","DRLL","IE00BGHQF524.EUR","PLTW","ERX","IE00B19Z9P08.USD","LU1046421795.USD","LU0345774391.USD","LU0889566641.SGD","LU1496350171.SGD","SG9999000418.SGD","LU2458330243.SGD","LU0708995401.HKD","LU2125154778.USD","LU2168564495.EUR","LU0106261372.USD","LU0256863811.USD","IGE","LU2129689431.USD","LU0672654240.SGD","BK4139","IE00BYQQ9H92.USD","LU0208291251.USD","LU0861579265.USD","PLTA","LU0792757196.USD","LU0061474960.USD","LU1548497426.USD","IE00BQXX3C00.GBP","IE00B19Z9505.USD","LU2023251221.USD","LU0069063385.USD","LU2168564222.USD","LU2210149790.SGD","SGXZ99366536.SGD","VDE","LU0300736062.USD","LU0266512127.USD","LU0942090050.USD","LU2095319765.USD","LU2168564149.EUR","IE00BQXX3F31.USD","LU0109391861.USD","LU0868494708.USD","WEEI","LU0122376428.USD","ADBG","BK4567","IE00B894F039.SGD","IE000M9KFDE8.USD","LU0368265418.SGD","LU1815333072.USD","LU0081259029.USD","LU0170899867.USD","LU1861558580.USD","LU1116320737.USD","BK4559","PLTI","BK4534","IE00B5TLWC47.USD","LU1778281490.HKD","LU2133065610.SGD","LU0158827948.USD","LU1712237335.SGD","LU0006306889.USD","LU0098860793.USD","LU0557290698.USD","LU0957791311.USD","LU2236285917.USD","ADBE","LU0345770993.USD","BK4550","AIPI","LU1720051017.SGD","IYE","PLOO","DIG","LU0965509010.AUD","SG9999001424.SGD","LU0278409577.USD","IE00BQXX3D17.EUR","LU1162221912.USD","IXC","LU1674673691.USD","LU1084165304.USD","LU2458330169.SGD","LU1074936037.SGD","LU0149725797.USD","LU0965509101.SGD","LU1430594728.SGD","LU0234572021.USD","PLTY","GUNZ","LU0082616367.USD","LU0265550359.USD","LU0654597011.USD","LU1116320901.HKD","IGV","LU1119994496.HKD","BK4570","PLT","LU2129689514.USD","XLE","LU1585245621.USD","LU0342679015.USD","LU1066051498.USD","LU0719512351.SGD","LU2168563687.JPY","LU2237438978.USD","IE00BZ9MQY76.HKD","LU2089284900.SGD","LU1623119135.USD","FENY","LU0868494617.USD","LU1066053197.SGD","IE00B19Z3581.USD","LU2357305700.SGD","LU0157215616.USD","LU0198837287.USD","LU0630314457.HKD","LU0788109394.HKD","LU1496350502.SGD","IE00B3CCJ963.GBP","LU2168564065.EUR","IE0009356076.USD","PLTG","SGXZ81514606.USD","BK4592","LU1720051108.HKD","BK4547","SG9999002521.SGD","LU0070302665.USD","CVX","LU1633808545.USD","BK4588","LU0345774631.USD","LU1823568750.SGD","LU2125154935.USD","LU1267930813.SGD","LU1430597077.USD","LU1929549753.HKD","LU1366333091.USD","PLTR","IE00B7SZLL34.SGD","LU0234570918.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647537101","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2647537101","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647537101?lang=en_us&edition=fundamental","pubTime":"2026-06-30 18:40","pubTimestamp":1782816035,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Larimar Therapeutics (LRMR) and Arrowhead Pharmaceut...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-238?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-238?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LRMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647420534","title":"Larimar Therapeutics selloff a buying opportunity, says Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2647420534","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647420534?lang=en_us&edition=fundamental","pubTime":"2026-06-30 17:55","pubTimestamp":1782813321,"startTime":"0","endTime":"0","summary":"Citi recommends buying Larimar Therapeutics (LRMR) shares on yesterday’s weakness. FDA feedback indicates the company’s current data package is suf...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/larimar-therapeutics-selloff-a-buying-opportunity-says-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/larimar-therapeutics-selloff-a-buying-opportunity-says-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4585","BK4588","BK4539","BK4139","LENZ","LRMR","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647930511","title":"Nomlabofusp Progress and Durable Efficacy Support Buy Rating on LRMR with Unchanged $25 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2647930511","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647930511?lang=en_us&edition=fundamental","pubTime":"2026-06-30 00:15","pubTimestamp":1782749742,"startTime":"0","endTime":"0","summary":"In a report released today, Francois Brisebois from LifeSci Capital maintained a Buy rating on Larimar Therapeutics, with a price target of $25.00....","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/nomlabofusp-progress-and-durable-efficacy-support-buy-rating-on-lrmr-with-unchanged-25-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/nomlabofusp-progress-and-durable-efficacy-support-buy-rating-on-lrmr-with-unchanged-25-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LRMR","PRGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647036370","title":"Larimar stumbles on safety news even as BLA submission kicks off","url":"https://stock-news.laohu8.com/highlight/detail?id=2647036370","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647036370?lang=en_us&edition=fundamental","pubTime":"2026-06-29 22:25","pubTimestamp":1782743113,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics (LRMR) shares slid on Monday after the company reported new safety findings from its open label study of nomlabofusp for Fried...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/larimar-stumbles-on-safety-news-even-as-bla-submission-kicks-off-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/larimar-stumbles-on-safety-news-even-as-bla-submission-kicks-off-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LRMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647137183","title":"Larimar Tumbles as Safety Concerns Resurface in Rare Disease Drug Study Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2647137183","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647137183?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:14","pubTimestamp":1782735246,"startTime":"0","endTime":"0","summary":"BUZZ-Larimar tumbles as safety concerns resurface in rare disease drug study update** Larimar Therapeutics'LRMR.Oshares fall 22.2% to $2.84 premarket** LRMR has begun rolling submission for acceleratedU.S. FDAapproval of its drug nomlabofusp, a daily injection for Friedreich's ataxia, a rare and progressive nerve disease**Company says FDAhas signaled that LRMR's existing data sufficient to support a full review, with a potential mid-2027 launch, if approved** Larimar reported cases of anaphylaxis in its latest study update, after similarsafety concernsflagged last year** Ten of 43 patients experienced anaphylaxis, a sudden and severe allergic reaction that can cause breathing problems, swelling and a drop in blood pressure** Long-term study data shows patients on the drug for one year improved protein levels and signs of clinical benefit** Company saysabout 21 of the 43 patientsin the ongoing study have dropped out** As of last close, stock down ~4% YTD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nL4N4310YD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LRMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647037629","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2647037629","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647037629?lang=en_us&edition=fundamental","pubTime":"2026-06-29 19:37","pubTimestamp":1782733022,"startTime":"0","endTime":"0","summary":"Farmmi  shares were down 68% in Monday premarket activity after the company announced a public offering of Class A ordinary shares.Jupiter Neurosciences  stock was down 22% after the company filed a prospectus for the resale of up to 16 million shares.Creative Realities  shares were down 19% after the company launched a public offering of common shares and pre-funded warrants.Larimar Therapeutics  stock was down 16%, following the previous session's 4.6% gain.PicoCELA  shares were down 16% after the previous session's 127% gain.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["JUNS","PCLA","BK4212","LRMR","BK4020","BK4007","BK4139","CREX","FAMI","BK4009"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647737813","title":"Larimar Therapeutics submits first module of rolling BLA for nomlabofusp","url":"https://stock-news.laohu8.com/highlight/detail?id=2647737813","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647737813?lang=en_us&edition=fundamental","pubTime":"2026-06-29 18:35","pubTimestamp":1782729306,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics (LRMR) announced it has submitted the first module of its rolling Biologics License Application submission to the FDA for acce...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/larimar-therapeutics-submits-first-module-of-rolling-bla-for-nomlabofusp-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/larimar-therapeutics-submits-first-module-of-rolling-bla-for-nomlabofusp-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4588","LENZ","LABU","LRMR","BK4007","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647373673","title":"Larimar Therapeutics Submits First Module of Rolling BLA to FDA for Nomlabofusp in Friedreich’s Ataxia","url":"https://stock-news.laohu8.com/highlight/detail?id=2647373673","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647373673?lang=en_us&edition=fundamental","pubTime":"2026-06-29 18:30","pubTimestamp":1782729025,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics submits first module of rolling BLA to FDA for nomlabofusp in Friedreich’s ataxiaLarimar Therapeutics submitted the first module of a rolling BLA to the FDA for accelerated approv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nNDL9TH4d1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0314104364.USD","LU2095319765.USD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","SG9999014005.SGD","IE00BN0W2T93.GBP","LRMR","BK4588","IE00BN0W2V16.EUR","SG9999014021.USD","NDAQ","LU2210149790.SGD","IE00BN0W2W23.USD","LU2210150020.SGD","SG9999014013.SGD","BK4585","SG9999014039.USD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647837362","title":"Larimar Therapeutics - First Patient Dosing in Phase 3 Study Expected Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2647837362","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647837362?lang=en_us&edition=fundamental","pubTime":"2026-06-29 18:30","pubTimestamp":1782729000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nTUA4YWZT6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LRMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647373936","title":"Larimar Therapeutics - Nomlabofusp Long-term Dosing Generally Well-tolerated; Anaphylaxis in 10 of 43 Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2647373936","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647373936?lang=en_us&edition=fundamental","pubTime":"2026-06-29 18:30","pubTimestamp":1782729000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nTUA4YWZT6:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LRMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647373933","title":"Larimar Therapeutics - Submits First Module of Rolling Bla for Nomlabofusp; Remaining Modules Expected 2H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2647373933","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647373933?lang=en_us&edition=fundamental","pubTime":"2026-06-29 18:30","pubTimestamp":1782729000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nTUA4YWZT6:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LRMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646860360","title":"Larimar Therapeutics to Host Investor Webcast on Nomlabofusp Program for Friedreich’s Ataxia","url":"https://stock-news.laohu8.com/highlight/detail?id=2646860360","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646860360?lang=en_us&edition=fundamental","pubTime":"2026-06-27 04:05","pubTimestamp":1782504327,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics to host investor webcast on nomlabofusp program for Friedreich’s ataxiaLarimar Therapeutics will host an investor webcast on June 29, 2026, at 7:45 a.m. ET.Event will cover a regu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nNDL2l4RWN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","SG9999014005.SGD","BK4588","IE00BN0W2T93.GBP","LU2210149790.SGD","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","LU0314104364.USD","BK4585","IE00B64PRP62.GBP","IE00BKPKM429.USD","SG9999014021.USD","SG9999014039.USD","IE00BGHQF748.EUR","LRMR","NDAQ","LU2095319765.USD","BK4112","IE00B3QW5Z07.USD","BK4139","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.larimartx.com","stockEarnings":[{"period":"1week","weight":0.0731},{"period":"1month","weight":0.2607},{"period":"3month","weight":-0.0096},{"period":"6month","weight":0.3388},{"period":"1year","weight":0.2417},{"period":"ytd","weight":0.0787}],"compareEarnings":[{"period":"1week","weight":0.0411},{"period":"1month","weight":0.0356},{"period":"3month","weight":0.0511},{"period":"6month","weight":0.1383},{"period":"1year","weight":0.2221},{"period":"ytd","weight":0.1311}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.583333,"avgChangeRate":0.088036},{"month":2,"riseRate":0.583333,"avgChangeRate":0.090114},{"month":3,"riseRate":0.25,"avgChangeRate":-0.145723},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.03405},{"month":5,"riseRate":0.416667,"avgChangeRate":-0.096181},{"month":6,"riseRate":0.5,"avgChangeRate":-0.004489},{"month":7,"riseRate":0.538462,"avgChangeRate":-0.000858},{"month":8,"riseRate":0.538462,"avgChangeRate":0.080954},{"month":9,"riseRate":0.416667,"avgChangeRate":0.000938},{"month":10,"riseRate":0.666667,"avgChangeRate":-0.029427},{"month":11,"riseRate":0.583333,"avgChangeRate":0.038429},{"month":12,"riseRate":0.583333,"avgChangeRate":0.050649}],"exchange":"NASDAQ","name":"Larimar Therapeutics, Inc.","nameEN":"Larimar Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Larimar Therapeutics, Inc.(LRMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Larimar Therapeutics, Inc.(LRMR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Larimar Therapeutics, Inc.,LRMR,Larimar Therapeutics, Inc.股票,Larimar Therapeutics, Inc.股票老虎,Larimar Therapeutics, Inc.股票老虎国际,Larimar Therapeutics, Inc.行情,Larimar Therapeutics, Inc.股票行情,Larimar Therapeutics, Inc.股价,Larimar Therapeutics, Inc.股市,Larimar Therapeutics, Inc.股票价格,Larimar Therapeutics, Inc.股票交易,Larimar Therapeutics, Inc.股票购买,Larimar Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Larimar Therapeutics, Inc.(LRMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Larimar Therapeutics, Inc.(LRMR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}